Vir Biotechnology (VIR) Competitors

$9.09 -0.24 (-2.57%)

Closing price 04:00 PM Eastern

Extended Trading

$9.10 +0.01 (+0.06%)

As of 04:22 PM Eastern

VIR vs. PTGX, COGT, BLTE, TERN, and CNTA

Should you buy Vir Biotechnology stock or one of its competitors? MarketBeat compares Vir Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vir Biotechnology include Protagonist Therapeutics (PTGX), Cogent Biosciences (COGT), Belite Bio (BLTE), Terns Pharmaceuticals (TERN), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry.

How does Vir Biotechnology compare to Protagonist Therapeutics?

Vir Biotechnology (NASDAQ:VIR) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Protagonist Therapeutics has higher revenue and earnings than Vir Biotechnology. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	22.36	-$437.99M	-$3.13	N/A
Protagonist Therapeutics	$74.06M	91.65	-$130.15M	-$1.81	N/A

Protagonist Therapeutics has a net margin of -154.88% compared to Vir Biotechnology's net margin of -638.88%. Protagonist Therapeutics' return on equity of -17.76% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 16.0% of Vir Biotechnology shares are held by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vir Biotechnology presently has a consensus price target of $20.25, suggesting a potential upside of 122.77%. Protagonist Therapeutics has a consensus price target of $113.69, suggesting a potential upside of 7.71%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, research analysts plainly believe Vir Biotechnology is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Vir Biotechnology had 8 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 22 mentions for Vir Biotechnology and 14 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.10 beat Vir Biotechnology's score of -0.02 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vir Biotechnology has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Vir Biotechnology on 11 of the 17 factors compared between the two stocks.

How does Vir Biotechnology compare to Cogent Biosciences?

Vir Biotechnology (NASDAQ:VIR) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Vir Biotechnology has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market.

65.3% of Vir Biotechnology shares are owned by institutional investors. 16.0% of Vir Biotechnology shares are owned by company insiders. Comparatively, 7.3% of Cogent Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cogent Biosciences has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Cogent Biosciences	N/A	-104.27%	-54.64%

Cogent Biosciences has lower revenue, but higher earnings than Vir Biotechnology. Cogent Biosciences is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	22.36	-$437.99M	-$3.13	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Vir Biotechnology currently has a consensus target price of $20.25, suggesting a potential upside of 122.77%. Cogent Biosciences has a consensus target price of $43.73, suggesting a potential upside of 27.89%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Vir Biotechnology is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, Vir Biotechnology had 16 more articles in the media than Cogent Biosciences. MarketBeat recorded 22 mentions for Vir Biotechnology and 6 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.98 beat Vir Biotechnology's score of -0.02 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cogent Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vir Biotechnology beats Cogent Biosciences on 10 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Belite Bio has a beta of -1.19, meaning that its share price is 219% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

Belite Bio currently has a consensus price target of $202.33, indicating a potential upside of 34.93%. Vir Biotechnology has a consensus price target of $20.25, indicating a potential upside of 122.77%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Belite Bio has higher earnings, but lower revenue than Vir Biotechnology. Belite Bio is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.30	N/A
Vir Biotechnology	$68.56M	22.36	-$437.99M	-$3.13	N/A

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 16.0% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Belite Bio has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Belite Bio's return on equity of -19.49% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-19.49%	-19.05%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

In the previous week, Vir Biotechnology had 13 more articles in the media than Belite Bio. MarketBeat recorded 22 mentions for Vir Biotechnology and 9 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.72 beat Vir Biotechnology's score of -0.02 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Vir Biotechnology beats Belite Bio on 10 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to Terns Pharmaceuticals?

Terns Pharmaceuticals (NASDAQ:TERN) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Terns Pharmaceuticals presently has a consensus price target of $55.14, indicating a potential upside of 4.13%. Vir Biotechnology has a consensus price target of $20.25, indicating a potential upside of 122.77%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Terns Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Terns Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Terns Pharmaceuticals has higher earnings, but lower revenue than Vir Biotechnology. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Terns Pharmaceuticals	N/A	N/A	-$96.21M	-$1.03	N/A
Vir Biotechnology	$68.56M	22.36	-$437.99M	-$3.13	N/A

In the previous week, Vir Biotechnology had 18 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 22 mentions for Vir Biotechnology and 4 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.08 beat Vir Biotechnology's score of -0.02 indicating that Terns Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Terns Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 1.5% of Terns Pharmaceuticals shares are held by insiders. Comparatively, 16.0% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Terns Pharmaceuticals has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Terns Pharmaceuticals' return on equity of -20.02% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Terns Pharmaceuticals	N/A	-20.02%	-19.37%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

Terns Pharmaceuticals has a beta of -0.37, meaning that its share price is 137% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

Summary

Vir Biotechnology beats Terns Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Vir Biotechnology compare to Centessa Pharmaceuticals?

Vir Biotechnology (NASDAQ:VIR) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Centessa Pharmaceuticals has lower revenue, but higher earnings than Vir Biotechnology. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	22.36	-$437.99M	-$3.13	N/A
Centessa Pharmaceuticals	$15M	393.97	-$197.53M	-$1.79	N/A

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 16.0% of Vir Biotechnology shares are held by insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Vir Biotechnology had 17 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 22 mentions for Vir Biotechnology and 5 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.41 beat Vir Biotechnology's score of -0.02 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Centessa Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vir Biotechnology presently has a consensus target price of $20.25, indicating a potential upside of 122.77%. Centessa Pharmaceuticals has a consensus target price of $40.70, indicating a potential upside of 2.78%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Vir Biotechnology is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Vir Biotechnology has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Summary

Vir Biotechnology beats Centessa Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Vir Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIR vs. The Competition

Export

Metric	Vir Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.53B	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-2.90	18.81	20.87	25.61
Price / Sales	22.36	181.76	521.62	63.45
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	1.89	6.75	9.86	6.71
Net Income	-$437.99M	$24.11M	$3.55B	$333.77M
7 Day Performance	-1.94%	0.11%	-0.26%	0.40%
1 Month Performance	-9.55%	0.87%	1.39%	4.03%
1 Year Performance	102.00%	78.18%	41.07%	36.33%

Vir Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIR Vir Biotechnology	3.1264 of 5 stars	$9.09 -2.6%	$20.25 +122.8%	+98.5%	$1.53B	$68.56M	N/A	580	Analyst Revision
PTGX Protagonist Therapeutics	1.7523 of 5 stars	$99.52 +1.2%	$108.15 +8.7%	+134.7%	$6.33B	$46.02M	N/A	120	Insider Trade
COGT Cogent Biosciences	3.3176 of 5 stars	$36.73 +0.3%	$43.45 +18.3%	+587.2%	$6.26B	N/A	N/A	80	Positive News Gap Down
BLTE Belite Bio	2.9554 of 5 stars	$154.51 -0.2%	$202.33 +31.0%	+152.1%	$6.19B	N/A	N/A	10
TERN Terns Pharmaceuticals	2.1161 of 5 stars	$52.97 +0.1%	$55.14 +4.1%	+1,725.9%	$6.11B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIR) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vir Biotechnology (VIR) Competitors

VIR vs. PTGX, COGT, BLTE, TERN, and CNTA

How does Vir Biotechnology compare to Protagonist Therapeutics?

Summary

How does Vir Biotechnology compare to Cogent Biosciences?

Summary

How does Vir Biotechnology compare to Belite Bio?

Summary

How does Vir Biotechnology compare to Terns Pharmaceuticals?

Summary

How does Vir Biotechnology compare to Centessa Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vir Biotechnology (VIR) Competitors

VIR vs. PTGX, COGT, BLTE, TERN, and CNTA

How does Vir Biotechnology compare to Protagonist Therapeutics?

Which has better earnings and valuation, VIR or PTGX?

Is VIR or PTGX more profitable?

Do institutionals & insiders have more ownership in VIR or PTGX?

Do analysts prefer VIR or PTGX?

Does the media favor VIR or PTGX?

Which has more risk and volatility, VIR or PTGX?

Summary

How does Vir Biotechnology compare to Cogent Biosciences?

Which has more volatility & risk, VIR or COGT?

Do insiders & institutionals hold more shares of VIR or COGT?

Is VIR or COGT more profitable?

Which has stronger earnings & valuation, VIR or COGT?

Do analysts recommend VIR or COGT?

Does the media prefer VIR or COGT?

Summary

How does Vir Biotechnology compare to Belite Bio?

Which has more volatility and risk, BLTE or VIR?

Do analysts prefer BLTE or VIR?

Which has better earnings & valuation, BLTE or VIR?

Do institutionals & insiders believe in BLTE or VIR?

Is BLTE or VIR more profitable?

Does the media favor BLTE or VIR?

Summary

How does Vir Biotechnology compare to Terns Pharmaceuticals?

Do analysts prefer TERN or VIR?

Which has stronger earnings and valuation, TERN or VIR?

Does the media prefer TERN or VIR?

Do insiders & institutionals have more ownership in TERN or VIR?

Is TERN or VIR more profitable?

Which has more volatility & risk, TERN or VIR?

Summary

How does Vir Biotechnology compare to Centessa Pharmaceuticals?

Which has higher valuation & earnings, VIR or CNTA?

Do institutionals & insiders have more ownership in VIR or CNTA?

Does the media refer more to VIR or CNTA?

Do analysts recommend VIR or CNTA?

Which has more risk & volatility, VIR or CNTA?

Is VIR or CNTA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools